Skip to main content
Premium Trial:

Request an Annual Quote

MoBiTec Distributing BellBrook HTS Platform in Germany

NEW YORK (GenomeWeb News) – German firm MoBiTec today announced a distribution deal in Germany for BellBrook Labs' high-throughput screening platform for enzymes.

Financial and other terms of the deal were not disclosed.

BellBrooks Labs' Transcreener HTS Assays is a high-throughput screening platform for enzymes based on direct detection of nucleotide enzyme products with far red fluorescence intensity, fluorescence polarization, and time resolved-fluorescence resonance energy transfer readouts, MoBiTec said. It added that the system allows for the screening of more targets, both well-characterized and emerging, more quickly and more efficiently.

The Transcreener assay method can also be used across entire families of nucleotide-dependent enzymes.

Based in Madison, Wis., BellBrook provides screening tools in order to accelerate new drug discovery work. Thermo Fisher Scientific said last month it would distribute the firm's array products.

MoBiTec offers research tools for molecular and cellular biology research.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.